Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 1/20 | 0.37 |
| ▸ | OGA | O60502 | 11/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30134226 | 0.90 | HDAC4 (0.42) | UGT2B7OGAHDAC4PLGPLAU | |
| SCHEMBL30134260 | 0.84 | OGA (0.39) | UGT2B7OGAHDAC4PLGPLAU | |
| SCHEMBL14243188 | 0.78 | ESR2 (0.40) | HDAC4PDE2APDE10A | |
| SCHEMBL30133769 | 0.76 | OGA (0.43) | UGT2B7OGAPLGPLAUPDE2A | |
| SCHEMBL30134314 | 0.76 | UGT2B7 (0.39) | UGT2B7OGAPLGPLAUPDE2A | |
| SCHEMBL30134297 | 0.75 | NT5E (0.44) | HDAC4CYP2C19 | |
| SCHEMBL30134306 | 0.73 | HDAC4 (0.41) | HDAC4 | |
| SCHEMBL30900015 | 0.73 | OGA (0.40) | UGT2B7OGAPLGPLAUPDE2A | |
| SCHEMBL30133952 | 0.73 | OGA (0.41) | UGT2B7OGAPLGPLAU | |
| SCHEMBL30134126 | 0.73 | CYP1A2 (0.39) | UGT2B7OGAPLGPLAUPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119119033-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-09-12 | — | — | US | disclosed |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-08-15 | — | — | US | disclosed |
| EP-4380936-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | BeiGene, Ltd. (KY) | 2024-06-12 | — | — | EP | disclosed |
| CN-117836296-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-2023011456-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | BEIGENE, LTD. (KY) | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300951-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | UGT2B7 2079/4885OGA 4451/4885HDAC4 691/4885 |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | UGT2B7 2079/4885OGA 4451/4885HDAC4 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.